PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
30.66
Positive P/E while Medical - Pharmaceuticals median is negative at -0.91. Peter Lynch would investigate competitive advantages in a distressed Medical - Pharmaceuticals.
3.36
P/S less than half the Medical - Pharmaceuticals median of 7.64. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
5.47
P/B exceeding 1.5x Medical - Pharmaceuticals median of 3.06. Jim Chanos would check for potential asset write-down risks.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.47
Fair value ratio exceeding 1.5x Medical - Pharmaceuticals median of 3.06. Jim Chanos would check for valuation bubble risks.
0.82%
Positive earnings while Medical - Pharmaceuticals median shows losses. Peter Lynch would examine earnings quality advantage.
No Data
No Data available this quarter, please select a different quarter.